Trevena inc   (TRVN)
Other Ticker:  
Price: $0.5709 $-0.01 -1.738%
Day's High: $0.6169 Week Perf: -1.14 %
Day's Low: $ 0.56 30 Day Perf: -10.92 %
Volume (M): 130 52 Wk High: $ 3.28
Volume (M$): $ 74 52 Wk Avg: $0.78
Open: $0.56 52 Wk Low: $0.51

 Market Capitalization (Millions $) 8
 Shares Outstanding (Millions) 14
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -31
 Cash Flow (TTM) (Millions $) 11
 Capital Exp. (TTM) (Millions $) 0

Trevena Inc
Trevena Inc. is a pharmaceutical company located in Pennsylvania, USA that is focused on discovering, developing and commercializing therapies for serious medical conditions. The company was founded in 2008 and is publicly traded on the NASDAQ stock exchange under the symbol TRVN.

Trevena is dedicated to advancing the care of patients suffering from pain, heart failure, and other conditions that have a significant impact on overall health and quality of life. The company's innovative drug discovery platform is based on a deep understanding of chemical biology and molecular pharmacology, which enables the development of highly specific and effective therapies.

The company's lead product candidate is OLINVYKe (oliceridine), which is a new pain reliever that has been approved by the U.S. Food and Drug Administration (FDA). OLINVYK is specifically designed to address the limitations of traditional opioid analgesics by providing rapid and effective pain relief, while also minimizing common side effects such as respiratory depression, nausea, and vomiting.

In addition to OLINVYK, Trevena has a strong pipeline of product candidates that are currently in various stages of development. These include TRV027, which is being developed for the treatment of acute heart failure, and TRV250, which is being developed for the treatment of migraine headaches.

Trevena's mission is to improve the lives of patients by developing and commercializing innovative therapies that address unmet medical needs. The company is committed to maintaining the highest standards of scientific excellence and ethical conduct, and is dedicated to working collaboratively with healthcare providers, patients, and other stakeholders to achieve its goals.

   Company Address: 955 Chesterbrook Boulevard, Suite 110 Chesterbrook 19087 PA
   Company Phone Number: 354-8840   Stock Exchange / Ticker: NASDAQ TRVN
   TRVN is expected to report next financial results on March 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Financing Agreement

Trevena Inc Closes $1946 Million Private Placement Offering and Sees Improved Leverage Ratio Performance

Published Thu, Dec 28 2023 7:00 PM UTC

Trevena Inc. Closes $1.946 Million Private Placement Offering and Sees Improved Leverage Ratio Performance
CHESTERBROOK, Pa., Dec. 28, 2023 - Trevena Inc., a biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with central nervous system (CNS) disorders, has successfully closed its previously announced private placement...

Clinical Study

Advancing Burn Care: Investigator-Initiated Study Explores the Use of OLINVYK in Acute Burn Injuries

Published Thu, Nov 30 2023 12:01 PM UTC

Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries Results from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in Chicago from April 9th-12th
Trevena, a biopharmaceutical company focused on developing and commercializing innovative therapies for pati...

Trevena Inc

Major Pharmaceutical Preparations Company's Surprising Quarter Boosts Stock Market with Operating Shortfall Decrease of $8.827 Million

Date: February XX, 2024
Investors and industry observers are closely analyzing Trevena Inc's third-quarter results for 2023, which indicate a positive surprise in the company's performance. Trevena Inc, a major player in the Pharmaceutical Preparations industry, reported an operating shortfall of $-8.827 million for the quarter, significantly better than the $-15.755 million shortfall reported in the same quarter a year ago.
This improvement in operating shortfall has instilled confidence in analysts, who see it as a step towards Trevena Inc's success in the healthcare sector. Furthermore, the diminishing returns have also shown significant improvement, decreasing from $-15.295 million in the third quarter of 2022 to $-7.930 million in the same period of 2023. This development indicates positive progress on Trevena Inc's journey to becoming a respected and successful healthcare company.

Trevena Inc

Trevena Inc Reports Impressive Revenue of $3.021 Million, Reflecting Positive Growth and Improved Financial Performance

Trevena Inc, a major pharmaceutical preparations company, recently announced its financial results for the most recent fiscal period. The company reported a revenue of $3.021 million, showcasing positive growth compared to the previous quarter. Moreover, Trevena Inc disclosed a net deficit of $-8.012 million, an improvement from the deficit of $-14.981 million reported in the same quarter the previous year. While the financial results indicate positive changes, the company's stock performance has faced setbacks in the market.
Financial Results:
In the most recent fiscal period, Trevena Inc experienced a significant increase in revenue, reaching $3.021 million. This growth suggests that the company's offerings and strategies are resonating with customers, potentially leading to an increased market presence. Moreover, the reported net deficit of $-8.012 million portrays an improvement over the previous year's deficit of $-14.981 million, reflecting the company's efforts to control expenses and enhance profitability.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com